Please assess the completion status of the following clinical trial:

Trial Title: Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* possible, probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria~* disease duration more than 6 months and less than 3 years~* best-sitting FVC between 50% and 95% of predicted normal~* continuously treated with 100 mg riluzole daily, for at least one month~* onset of progression weakness within 36 months prior to study~* women of childbearing age be non-lactating and surgically sterile or using a highly effective method of birth control and have a negative pregnancy test~* capable of thoroughly understanding all information given and giving full informed consent according to GCP~Exclusion Criteria:~* previous participation in another clinical study within the preceding three months~* tracheotomy or assisted ventilation of any type during the preceding three months~* gastrostomy~* any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS~* presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment~* confirmed hepatic insufficiency or abnormal liver function (ASAT and/or ALAT more than 1.5 upper limit of normal)~* renal insufficiency (serum creatinine more than 2.26 mg/dl)~* evidence of major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms~* known hypersensitivity to any component of the study drugs~* likely to be not cooperative or comply with the trial requirements (as assessed by the investigator), or unable to be reached in the case of an emergency~* other antidiabetics~* heart failure or heart failure in the patients history (NYHA I to IV)~* history of macular oedema~* treatment with thiazolidinediones within 3 months prior to screening~* known or suspected history of alcohol and/or drug abuse~* treatment with gemfibrozil within 3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).